½ÃÀ庸°í¼­
»óǰÄÚµå
1759270

¿ø½Ã ½ÃÀå - ¼¼°è ¹× Áö¿ªº° ºÐ¼® : ±¹°¡º°, Áö¿ªº° - ºÐ¼®°ú ¿¹Ãø(2025-2035³â)

Hyperopia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: BIS Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¿ø½Ã´Â ´«ÀÇ ±¼ÀýÀÌ»óÀ¸·Î ÀϹÝÀûÀ¸·Î ¿ø½Ã·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù.

¾È±¸¿¡ µé¾î¿Â ºûÀÌ ¸Á¸·¿¡ Á÷Á¢ ÃÊÁ¡À» ¸Î´Â °ÍÀÌ ¾Æ´Ï¶ó ¸Á¸·ÀÇ µÚÂÊ¿¡ ÃÊÁ¡À» ¸Î±â ¶§¹®¿¡ °¡±î¿î °ÍÀº È帴ÇÏ°Ô º¸ÀÌ°í ¸Õ °ÍÀº ¼±¸íÇÏ°Ô º¸ÀÔ´Ï´Ù. ¿ø½Ã´Â ¾È±¸°¡ ³Ê¹« ª°Å³ª °¢¸·ÀÇ °î·üÀÌ ºÒÃæºÐÇÏ¿© ¹ß»ýÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¼±ÃµÀûÀÎ °æ¿ìµµ ÀÖÀ¸¸ç, ±× Á¤µµ´Â ´Ù¾çÇÕ´Ï´Ù. ¿ø½ÃÀÇ Áõ»óÀ¸·Î´Â µ¶¼­ °ï¶õ, ´«ÀÇ ÇÇ·Î, µÎÅë, °¡±î¿î °÷À» º¼ ¶§ È帴ÇÏ°Ô º¸ÀÌ´Â Áõ»ó µîÀÌ ÀÖ½À´Ï´Ù. ¿ø½Ã´Â º¸Åë ¾È°æ, ÄÜÅÃÆ®·»Áî ¶Ç´Â ¶ó½Ä¼ö¼ú°ú °°Àº ±¼Àý±³Á¤¼ö¼ú·Î ±³Á¤ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿ø½Ã ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â Àα¸ÀÇ °í·ÉÈ­ÀÔ´Ï´Ù. ³ªÀ̰¡ µé¾î°¨¿¡ µû¶ó °¡±î¿î »ç¹°¿¡ ÃÊÁ¡À» ¸ÂÃß´Â ´«ÀÇ ÀÚ¿¬Àû ´É·ÂÀº ³ë¾ÈÀ¸·Î ¾Ë·ÁÁø ³ë¾È »óÅ·Π°¨¼ÒÇϴµ¥, ÀÌ´Â ¿ø½Ã¿Í ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿¡ µû¶ó ¿ø½Ã ¹× ³ë¾È ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½Ã·Â ±³Á¤ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½º¸¶Æ®Æù, ÄÄÇ»ÅÍ, ÅÂºí¸´ µî µðÁöÅÐ ±â±âÀÇ »ç¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó µðÁöÅÐ ´«ÀÇ ÇǷΰ¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿ø½Ã Áõ»óÀ» ¾ÇÈ­½ÃŰ´Â ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ¾È°æ, ÄÜÅÃÆ®·»Áî, ÷´Ü ·¹ÀÌÀú ½Ã·Â±³Á¤¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡ÇÏ¿© ¿ø½Ã ½ÃÀåÀÇ Å« ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ç¿ë °¡´ÉÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¿Í ¾È°æ ±â¼úÀÇ ¹ßÀüµµ ½ÃÀå ±âȸ È®´ë¿¡ ÀÏÁ¶Çϰí ÀÖ½À´Ï´Ù.

¿ø½Ã ½ÃÀåÀÇ ¼ºÀå¿¡µµ ºÒ±¸Çϰí, ¸î °¡Áö ¹®Á¦µéÀÌ °è¼Ó ±× ¹ßÀüÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä °úÁ¦ Áß Çϳª´Â ³ôÀº Ä¡·á ºñ¿ë, ƯÈ÷ ·¹ÀÌÀú ¾È°ú ¼ö¼ú(¶ó½Ä, PRK µî) ¹× °í±Þ ÄÜÅÃÆ®·»Áî¿Í °°Àº °í±Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ³ôÀº ºñ¿ëÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á´Â Àå±âÀûÀ¸·Î ÇýÅÃÀ» Á¦°øÇÏÁö¸¸, ƯÈ÷ ½ÅÈï ½ÃÀåÀ̳ª Á¾ÇÕÀûÀÎ ÀÇ·á º¸Çè¿¡ °¡ÀÔÇÏÁö ¾ÊÀº °³Àο¡°Ô´Â Ãʱ⠺ñ¿ëÀÌ ¸¹Àº ȯÀڵ鿡°Ô À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ç¿ë °¡´ÉÇÑ Ä¡·á¹ý°ú Á¤±âÀûÀÎ ¾È°ú °ËÁøÀÇ Çʿ伺¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·Àº Á¾Á¾ Áø´ÜÀ» Áö¿¬½ÃÄÑ ÇÕº´Áõ°ú ¿ø½Ã ¾ÇÈ­¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ¹®Á¦´Â ¾ÈÀü¼º, ÀáÀçÀû ºÎÀÛ¿ë ¶Ç´Â ¼ö¼úÀÇ À§Ç輺¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ¼ö¼úÀû °³ÀÔ¿¡ ´ëÇÑ È¯ÀÚÀÇ °ÅºÎ°¨ÀÔ´Ï´Ù. ¸¶Áö¸·À¸·Î, ¾È°æÀ̳ª ÄÜÅÃÆ®·»Áî´Â ÀϹÝÀûÀÎ ÇØ°áÃ¥ÀÌÁö¸¸ ¿µ±¸ÀûÀÎ ÇØ°áÃ¥Àº ¾Æ´Ï¸ç, ¸¹Àº ȯÀÚµéÀÌ Áö¼ÓÀûÀÎ À¯Áö °ü¸®¿Í ÀæÀº ±³Ã¼°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ Àå±âÀûÀ¸·Î Å« ºÎ´ãÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

Essilor Luxottica, AbbVie Inc.(Allergan), Bausch Health Companies Inc. Essilor Luxottica´Â ±¤¹üÀ§ÇÑ ¾È°æ ¹× ·»Áî Æ÷Æ®Æú¸®¿À¸¦ ÅëÇØ ½ÃÀåÀ» ¼±µµÇϰí ÀÖÀ¸¸ç, ¿ø½Ã Ä¡·á ¹× ½Ã·Â ±³Á¤À» À§ÇÑ ÃÖ÷´Ü ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. AbbVie(Allergan)´Â ¿ø½Ã¿ëÀ¸·Î Á¶Á¤µÈ °íÇØ»óµµ ·»Áî¿Í ´©Áø´ÙÃÊÁ¡ ·»Á Á¦°øÇϰí, Bausch Health´Â Bausch + Lomb¸¦ ÅëÇØ ÄÜÅÃÆ®·»Áî¿Í ·¹ÀÌÀú ¼ö¼ú¿¡ ´ëÇÑ »õ·Î¿î ¾à¸®ÇÐÀû Ä¡·áÁ¦ÀÎ Vuity¸¦ Ãâ½ÃÇß½À´Ï´Ù. Lomb¸¦ ÅëÇØ ÄÜÅÃÆ®·»Áî¿Í ·¹ÀÌÀú ¼ö¼ú ±â¼úÀ» ¸ðµÎ Á¦°øÇϰí ÀÖÀ¸¸ç, AlconÀº ÷´Ü ¶ó½Ä ¹× ÄÜÅÃÆ®·»Áî¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. The Cooper Companies Inc.´Â ÄíÆÛºñÀü(Cooper Vision) ºê·£µå¸¦ ÅëÇØ ÄÜÅÃÆ®·»Áî Àü¹® ±â¾÷À¸·Î¼­ ¿ø½Ã¸¦ À§ÇÑ °íǰÁú ¼Ö·ç¼ÇÀ» Á¦°øÇϰí ÀÖÀ¸¸ç, Orasis Pharmaceuticals´Â ³ë¾È°ú ¿ø½Ã¸¦ ¼ö¼ú ¾øÀÌ Ä¡·áÇÏ´Â CSF-1°ú °°Àº À¯¸ÁÇÑ ÀǾàǰÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. Regeneron Pharmaceuticals´Â ¾È°ú Áúȯ ¿¬±¸·Î À¯¸íÇÏÁö¸¸, ´õ ³ÐÀº ¾È°ú ½ÃÀå¿¡µµ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â À§Ä¡¿¡ ÀÖ½À´Ï´Ù. ÀÌ È¸»ç´Â Çõ½ÅÀûÀÎ Á¦Ç°°ú Ä¡·á¹ý °³¹ß·Î ¾÷°è¸¦ ¼±µµÇϰí ÀÖÀ¸¸ç, ¿ø½Ã¸¦ È¿°úÀûÀ¸·Î Ä¡·áÇÏ°í ½Ã·Â ±³Á¤ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â ´Ù¾çÇÑ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­:

¼¼ºÐÈ­ 1: Áö¿ªº°

  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç

¼¼°è ¿ø½Ã ½ÃÀåÀº ¿ø½Ã °ü¸® ¹× Ä¡·á ¹æ¹ýÀ» À籸¼ºÇÏ´Â »õ·Î¿î Æ®·»µå¿¡ ÈûÀÔ¾î Å« º¯È­ÀÇ ½Ã±â¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­ÀÇ ÁÖ¿ä ¿øµ¿·ÂÀº ¶ó½Ä ¹× PRK¿Í °°Àº ·¹ÀÌÀú ¼ö¼ú ±â¼úÀÇ ¹ßÀüÀ¸·Î, º¸´Ù Á¤È®ÇÏ°í ´ú ħ½ÀÀûÀ̸ç, º¸´Ù ±¤¹üÀ§ÇÏ°Ô »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¿ø½Ã ¼ö¼ú Ä¡·á¸¦ º¸´Ù Ä£¼÷Çϰí È¿°úÀûÀ¸·Î ¸¸µé¾úÀ¸¸ç, ȸº¹ ½Ã°£À» ´ÜÃàÇÏ°í ¼º°ø·üÀ» ³ô¿´½À´Ï´Ù.

¶ÇÇÑ, Àå½Ã°£ ½ºÅ©¸° »ç¿ëÀ¸·Î ÀÎÇÑ µðÁöÅÐ ´«ÀÇ ÇÇ·Î µî °³ÀÎÀÇ ´ÏÁî º¯È­¿¡ ´ëÀÀÇÏ´Â ½º¸¶Æ® ¾ÆÀÌ¿þ¾î¿Í ¾î´ðƼºê ·»ÁîÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ö¿ä º¯È­¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¢ ¾÷üµéÀº °³ÀÎ ¸ÂÃãÇü ½Ã·Â ±³Á¤ ¼Ö·ç¼Ç¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ¿ø½ÃÀο¡°Ô Æí¾ÈÇÔ°ú Á¤È®¼ºÀ» Á¦°øÇÏ´Â ¸ÂÃãÇü ÄÜÅÃÆ®·»Áî¿Í °íÈ­Áú ¾È°æÀ» Á¦°øÇÕ´Ï´Ù. ³ë¾È(¿ø½Ã¿Í °ü·ÃµÈ Áõ»ó)À» À§ÇÑ ¾È¾à°ú °°Àº ÀǾàǰ Ä¡·á Áõ°¡´Â ½Ã·Â ±³Á¤À» À§ÇÑ ºñ¼ö¼úÀû ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ´« °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í, ºí·ç¶óÀÌÆ® Â÷´Ü ·»Á ´ÙÃÊÁ¡ ÄÜÅÃÆ®·»Áî¿Í °°Àº ÇÕ¸®ÀûÀÎ °¡°Ý´ëÀÇ ¼Ö·ç¼Ç Áõ°¡µµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ÀüüÀûÀ¸·Î ¿ø½Ã ½ÃÀåÀ» º¯È­½Ã۰í ÀÖÀ¸¸ç, º¸´Ù ¸¹Àº ¼ÒºñÀÚµéÀÌ º¸´Ù È¿°úÀûÀ̰í, Á¢±ÙÇϱ⠽¬¿ì¸ç, °³Àο¡°Ô ¸Â´Â Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ¿ø½Ã ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² ±¹°¡º°/Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

Á¦1Àå ¼¼°èÀÇ ¿ø½Ã ½ÃÀå : ¾÷°è Àü¸Á

  • ¼­·Ð
  • ½ÃÀå µ¿Çâ
  • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
  • ¿ªÇÐ ºÐ¼®
  • ÀÓ»ó½ÃÇè ºÐ¼®
  • ½ÃÀå ¿ªÇÐ

Á¦2Àå ¼¼°èÀÇ ¿ø½Ã ½ÃÀå(Áö¿ªº°), 2023³â-2035³â

  • ºÏ¹Ì
  • À¯·´

Á¦3Àå ¼¼°èÀÇ ¿ø½Ã ½ÃÀå : °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

  • ÁÖ¿ä Àü·«°ú °³¹ß
    • ÀμöÇÕº´(M&A)
    • ½Ã³ÊÁö Ȱµ¿
    • »ç¾÷ È®´ë¿Í ÀÚ±ÝÁ¶´Þ
    • Á¦Ç° ¹ß¸Å¿Í ½ÂÀÎ
    • ±âŸ Ȱµ¿
  • ±â¾÷ °³¿ä
    • Essilor Luxottica
    • AbbVie Inc.(Allergan)
    • Bausch Health Companies Inc.
    • Alcon Inc.
    • The Cooper Companies Inc.
    • Orasis Pharmaceuticals
    • Regeneron Pharmaceuticals

Á¦4Àå Á¶»ç ¹æ¹ý

LSH

Global Hyperopia Market, Analysis and Forecast: 2025-2035

Hyperopia is a refractive error in the eye, commonly known as farsightedness. It occurs when light entering the eye is focused behind the retina rather than directly on it, making nearby objects appear blurred while distant objects are seen more clearly. Hyperopia is often caused by the eye being too short or the cornea having insufficient curvature. The condition can be present from birth, and its severity can vary. Symptoms of hyperopia may include difficulty reading, eye strain, headaches, and blurred vision for close-up tasks. It is typically corrected with glasses, contact lenses, or refractive surgeries like LASIK to help focus light properly onto the retina.

One of the key drivers of the Hyperopia market is the aging population. As people age, the natural ability of the eye to focus on close objects diminishes, a condition known as presbyopia, which is closely related to hyperopia. With the global population aging, the incidence of hyperopia and presbyopia is increasing, leading to a higher demand for vision correction solutions. Additionally, the growing use of digital devices like smartphones, computers, and tablets is contributing to digital eye strain, which exacerbates the symptoms of hyperopia. This has further fueled the demand for glasses, contact lenses, and advanced laser vision correction procedures, driving significant growth in the hyperopia market. The increasing awareness of available treatments and advancements in eyewear technology also play a role in expanding market opportunities.

Despite the growth of the Hyperopia market, several challenges continue to hinder its progress. One of the primary challenges is the high cost of treatments, particularly for advanced solutions like laser eye surgeries (such as LASIK or PRK) and premium contact lenses. While these treatments can offer long-term benefits, the initial cost can be a barrier for many patients, especially in emerging markets or for individuals without comprehensive health insurance coverage. Additionally, the lack of awareness about available treatments and the need for regular eye exams often results in delayed diagnosis, which can lead to complications or worsening of hyperopia. Another challenge is the patient resistance to surgical interventions due to concerns about safety, potential side effects, or the perceived risks of surgery. Lastly, while eyeglasses and contact lenses are common solutions, they do not provide a permanent fix, and many individuals require ongoing maintenance or frequent replacements, which can be a significant burden over time.

The global Hyperopia market is highly competitive, with several leading companies driving innovation and market growth. Companies such as Essilor Luxottica, AbbVie Inc. (Allergan), Bausch Health Companies Inc., Alcon Inc., The Cooper Companies Inc., Orasis Pharmaceuticals, and Regeneron Pharmaceuticals are at the forefront of providing cutting-edge solutions for hyperopia treatment and vision correction. Essilor Luxottica dominates the market with its extensive portfolio of eyewear and lenses, offering high-definition lenses and progressive lenses tailored for hyperopia. AbbVie (Allergan) has introduced Vuity, a novel pharmacologic treatment for presbyopia, a condition related to hyperopia. Bausch Health, through its Bausch + Lomb division, provides both contact lenses and laser surgery technologies, while Alcon focuses on advanced LASIK and contact lenses. The Cooper Companies Inc., with its CooperVision brand, specializes in contact lenses, offering high-quality solutions for hyperopia. Orasis Pharmaceuticals is developing promising pharmaceutical treatments like CSF-1 to treat presbyopia and hyperopia non-surgically. Regeneron Pharmaceuticals, although known for its work in ocular diseases, is also positioned to influence the broader eye care market. These companies are leading the way in developing innovative products and therapies, offering a wide range of options to effectively treat hyperopia and meet the growing demand for vision correction solutions.

Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global Hyperopia market is undergoing significant transformation, fueled by emerging trends that are reshaping the way hyperopia is managed and treated. Key drivers of this transformation include advancements in laser surgery technologies like LASIK and PRK, which are becoming more precise, less invasive, and more widely available. These innovations are making surgical treatments for hyperopia more accessible and effective, with quicker recovery times and higher success rates.

Additionally, the increasing adoption of smart eyewear and adaptive lenses that cater to the changing needs of individuals, especially in the context of digital eye strain caused by prolonged screen time, is contributing to a shift in market demand. Companies are also focusing on personalized vision correction solutions, offering customized contact lenses and high-definition eyeglasses that provide greater comfort and precision for individuals with hyperopia. The rise in pharmaceutical treatments, such as eye drops for presbyopia (a condition often linked to hyperopia), is further driving market growth by providing non-surgical alternatives for vision correction. The growing awareness of eye health and the increasing availability of affordable solutions, including blue light-blocking lenses and multifocal contact lenses, are also contributing to the expanding market. These trends are collectively transforming the hyperopia market, making treatments more effective, accessible, and personalized for a wider range of consumers.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Hyperopia Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Hyperopia Market (Region), ($Billion), 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Hyperopia Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Hyperopia Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Hyperopia Market, by Country
        • 2.3.3.1.1 China
        • 2.3.3.1.2 Japan

3. Global Hyperopia Market: Competitive Landscape and Company Profiles

  • 3.1 Key Strategies and Development
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 Essilor Luxottica
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 AbbVie Inc. (Allergan)
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Bausch Health Companies Inc.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Alcon Inc.
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 The Cooper Companies Inc.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Orasis Pharmaceuticals
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
    • 3.2.7 Regeneron Pharmaceuticals
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View

4. Research Methodology

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦